Transfusion Medicine Reviews
Volume 22, Issue 2 , Pages 133-153 , April 2008

Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation

References 

  1. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA. 2003;289:959–962
  2. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction?. Blood. 2001;97:1180–1195
  3. Lee JH, Klein HG. From leukocyte reduction to leukocyte transfusion: The immunological effects of transfused leukocytes. Baillieres Best Pract Res Clin Haematol. 2000;13:585–600
  4. Gould DS, Auchincloss HJ. Direct and indirect recognition: The role of MHC antigens in graft rejection. Immunol Today. 1999;20:77–82
  5. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusions. Lancet. 2004;363:417–421
  6. Hewitt PE, Llewelyn CA, Mackenzie J, et al. Creutzfeldt-Jakob disease and blood transfusion: Results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang. 2006;91:221–230
  7. Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet. 2006;368:2061–2067
  8. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527–529
  9. Blajchman MA. Bacterial contamination of cellular blood components: Risks, sources and control. Vox Sang. 2004;87(Suppl):98–103
  10. US Food and Drug Administration . Minutes of 36th Meeting of the Blood Product Advisory Committee; 1992, May 28–29; Bethesda, Maryland. Washington (DC): USFDA; 1992;
  11. Yomtovian R, Lazarus HM, Goodnough LT, et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion. 1993;33:902–909
  12. Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol. 2002;117:275–287
  13. Saunders C, Herbert P, Rowe G, et al. In vitro evaluation of the PALL Leukotrap Affinity Prion Reduction Filter as a secondary device following primary leucoreduction. Vox Sang. 2005;89:220–228
  14. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev. 2004;18:11–24
  15. Cohen ND, Munoz A, Reitz BA. Transmission of retroviruses by transfusion of screened blood in patients undergoing cardiac surgery. N Engl J Med. 1989;320:1172–1176
  16. Nelson KE, Donahue JG, Munoz A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med. 1992;117:554–559
  17. Grant IH, Gold JW, Wittner M, et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med. 1989;111:849–851
  18. Leiby DA, Lenes BA, Tibbals MA, et al. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med. 1999;341:1237–1239
  19. Wu DG, Mason B, Jong J, et al. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion. 2005;45:1003–1010
  20. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US. Transfusion. 2002;43:1007–1017
  21. Custer B, Tomasulo PA, Murphy EL, et al. Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: Analysis of 2003 data to inform 2004 decision making. Transfusion. 2004;44:1547–1554
  22. Hellstern P. Solvent/detergent-treated plasma: Composition, efficacy, and safety. Curr Opin Hematol. 2004;11:346–350
  23. Williamson LM, Cardigan R, Prowse CV. Methylene blue–treated fresh-frozen plasma: What is its contribution to blood safety?. Transfusion. 2003;43:1322–1339
  24. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant. 2004;33:1–7
  25. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44:1496–1504
  26. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion. 2005;45:580–590
  27. Unna K, Greslin JG. Studies on the toxicity and pharmacology of riboflavin. J Pharmacol. 1942;76:75–80
  28. Hayashi M, Kishi M, Sofuni T, et al. Micronucleus tests in mice on 39 food additives and eight miscellaneous chemicals. Food Chem Toxicol. 1988;26:487–500
  29. Kuhn R, Boulanger P. Uber die Giftigkeit der Flavine. Hoppe Seylers Z Physiol Chem. 1936;241:233–238
  30. Studer A, Zbinden G, Uehlinger E. Die pathologie der avitaminosen and hypervitaminosen. In:  Buchner F,  Letterer E,  Roulet F editor. Handbuch der Allgemeinen Pathologie. Band II:Berlin: Springer Verlag; 1962;p. 734–987
  31. Williams JR, Grantham PH, Yamamoto RS, et al. Effect of dietary riboflavin on azo dye reductase in liver and in bacteria of cecal contents of rats. Biochem Pharmacol. 1970;19:2523–2525
  32. Scotto JM, Stralin HG, Lageron A, et al. Influence of carbon tetrachloride or riboflavin on liver carcinogenesis with a single dose of aflatoxin b1. Br J Exp Pathol. 1975;56:133–138
  33. Leclerc J. Influence of thiamine, riboflavin and vitamin B6 content in food on tissue content of these vitamins in the female lactating rat and young rats. Ann Nutr Aliment. 1974;28:11–20
  34. Lim-Sylianco C. Genotoxic studies of street soils in Quezon City, Philippines. In:  Sumino K editors. Environmental and occupational chemical hazards, no. 8. Proceedings of the Asia-Pacific Symposium in Environmental and Occupational Toxicology, 1987, Oct 4–10; Singapore. Kobe, Japan: Kobe University School of Medicine; 1987;
  35. Munoz N, Hayashi M, Bang LJ, et al. Effect of riboflavin, retinol, and zinc on micronuclei of buccal mucosa and of esophagus: A randomized double-blind intervention study in China. J Natl Cancer Inst. 1987;79:687–691
  36. Sugiyama M, Ando A, Nakao K, et al. Influence of vitamin B2 on formation of chromium(V), alkali-labile sites, and lethality of sodium chromate(VI) in Chinese hamster V-79 cells. Cancer Res. 1989;49:6180–6184
  37. Haveland-Smith RB. Evaluation of the genotoxicity of some natural food colours using bacterial assays. Mutat Res. 1981;91:285–290
  38. De Flora S. Study of 106 organic and inorganic compounds in the Salmonella/microsome test. Carcinogenesis. 1981;2:283–298
  39. Kale H, Harikumar P, Nair PM, et al. Assessment of the genotoxic potential of riboflavin and lumiflavin. Mutat Res. 1992;298:9–16
  40. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr. 1996;63:54–66
  41. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. J Photochem Photobiol. 2004;80:15–21
  42. Hardwick CC, Herivel TR, Hernandez SC, et al. Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology. J Photochem Photobiol. 2004;80:609–615
  43. Holmstrom B. Spectral studies of the photobleaching of riboflavin phosphate. Arkiv for Kemi. 1964;22:281–301
  44. Dekker RH, Srinivasan BN, Huber JR, et al. Photochemistry of flavins—I. Conventional and laser flash photolysis study of alloxazines. J Photochem Photobiol. 1973;18:457–466
  45. Koziol J. Studies of flavins in organic solvents—I. Spectral characteristics of riboflavin, riboflavin tetrabutyrate and lumichrome. J Photochem Photobiol. 1966;5:41–54
  46. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–885
  47. Fast LD, DiLeone G, Cardarelli G, et al. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag 2−/−gc−/− double knockout mice. Transfusion. 2006;46:1553–1560
  48. Fast LD, DiLeone G, Li J, et al. Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006;46:642–648
  49. Cardo LJ, Rentas FJ, Ketchum L, et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion. 2006;90:85–91
  50. Rentas FJ, Harman R, Salata J, et al. Inactivation of Orientia tsutsugamushi in RBCs, plasma, and platelets using riboflavin and light, as demonstrated in an animal model. Transfusion. 2007;47:240–247
  51. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: Comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang. 2004;87:82–90
  52. Li J, Lockerbie O, de Korte D, et al. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion. 2005;45:920–926
  53. Kumar V, Motheral T, Luzniak G, et al. Mirasol (TM) plasma pathogen reduction technology: Riboflavin-based process conserves, protein C, protein S and antithrombin activities. Transfusion. 2003;43(Suppl):80A;(abstr)
  54. Kumar V, Motheral T, Luzniak G, et al. Mirasol (TM) pathogen reduction technology: Riboflavin-based process retains functional activities of immumoglobulins. Transfusion. 2003;43(Suppl):80A;(abstr)
  55. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45:911–919
  56. Goodrich RP, Li J, Pieters H, et al. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang. 2006;90:279–285
  57. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45:1335–1341
  58. WHO . Twenty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. Evaluation of certain food additives. Tech Rep Ser. 1981;669:1–48
  59. EVM. Expert Group on Vitamins and Minerals; revised review of riboflavin. 2002. 1-48
  60. Federation of American Societies for Experimental Biology . Evaluation of the health aspects of riboflavin and riboflavin-5`-phosphate as food ingredients, SCOGS-114. In: Life Sciences Research Office, Federation of American Societies for Experimental Biology, Bethesda, Maryland. Prepared for US Food and Drug Administration, Washington, DC. 1979;p. 1–25
  61. In:  Martindale W,  Sweetman SC editor. The complete drug reference. 33rd ed.. London, UK: Pharmaceutical Press; 2002;p. 1386
  62. BIBRA . In: Working Group: Riboflavin and its derivatives: toxicity profile. Epscm, Surrey, UK: BIBRA; 1990;p. 1–7
  63. Direct Food Substances Affirmed as Generally Recognized as Safe; Riboflavin. 21 CFR Sect. 184.1695. 2001;
  64. European Commission Health and Consumer Protection Directorate-General, Scientific Committee on Food . In: Opinion of the Scientific Committee on Food on the tolerable upper intake level of vitamin B2.. Brussels, Belgium: European Commission; 2000;p. 1–10
  65. Sisson TR, Kendall N, Shaw E, et al. Phototherapy of jaundice in the newborn infant. II. Effect of various light intensities. J Pediatr. 1972;81:35–38
  66. Sisson TR. Photodegradation of riboflavin in neonates. Fed Proc. 1987;46:1883–1885
  67. Bates CJ. Human requirements for riboflavin. Am J Clin Nutr. 1987;46:122–123
  68. Kostenbauder HB, DeLuca PP, Kowarski CR. Photobinding and photoreactivity of riboflavin in the presence of macromolecules. J Pharm Sci. 1965;54:1243–1251
  69. Yurdakok M, Erdem G, Tekinalp G. Riboflavin in the treatment of neonatal hyperbilirubinemia. Turk J Pediatr. 1988;30:159–161
  70. Olsen JH, Hertz H, Kjaer SK, et al. Childhood leukemia following phototherapy for neonatal hyperbilirubinemia (Denmark). Cancer Causes Control. 1996;7:411–414
  71. Speck WT, Rosenkranz HS. Phototherapy for neonatal hyperbilirubinemia—A potential environmental health hazard to newborn infants: A review. Environ Mutagen. 1979;1:321–336
  72. Maisels MA, Kring EA. Does intensive phototherapy produce hemolysis in newborns of 35 or more weeks of gestation?. J Perinatol. 2006;26:498–500
  73. Stein G, Sperschneider H, Koppe S. Vitamin levels in chronic renal failure and need for supplementation. Blood Purif. 1985;3:52–62
  74. Allman MA, Truswell AS, Tiller DJ, et al. Vitamin supplementation of patients receiving haemodialysis. Med J Aust. 1989;150:130–133
  75. Gentile MG, Porrini M, Manna GM, et al. Water- and fat-soluble vitamin status in chronic renal insufficiency patients. Contrib Nephrol. 1992;98:89–97
  76. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet. 1998;352:291–292
  77. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology. 1998;50:466–470
  78. Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet. 1999;353:901–902
  79. International Organisation for Standardisation . International Standard ISO 10993 biological evaluation of medical devices—Part 1: Evaluation and testing. Geneva, Switzerland: International Organisation for Standardisation; 2003;
  80. International Organisation for Standardisation . International Standard ISO 10993 biological evaluation of medical devices—Part 11: Tests for systemic toxicity. Geneva, Switzerland: International Organisation for Standardisation; 1993;
  81. International Organisation for Standardisation. International Standard ISO 10993 biological evaluation of medical devices—Part 10: Tests for irritation and sensitization. Geneva, Switzerland: International Organisation for Standardisation; 1995;
  82. International Conference on Harmonisation of Technical Requirements for Pharmaceuticals (ICH): M3(R1) nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals. Geneva, Switzerland: ICH; 1997;
  83. Ames B, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975;31:347–364
  84. Green MHL, Muriel WJ. Mutagen testing using trp+ reversion in Escherichia coli. Mutat Res. 1976;38:3–32
  85. Evans HJ. Cytological methods for detecting chemical mutagens. In:  Hollaender A editors. Chemical mutagens, principles and methods for their detection. vol. 4:New York (NY): Plenum Press; 1976;
  86. Swierenga SHH, Heddle JA, Sigal EA, et al. Recommended protocols based on a survey of current practice in genotoxicity testing laboratories, IV. Chromosome aberration and sister-chromatid exchange in Chinese hamster ovary, V79 Chinese lung and human lymphocyte cultures. Mutat Res. 1991;246:301–322
  87. Galloway SM, Ardema AMJ, Ishidate MJ, et al. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res. 1994;312:241–261
  88. Heddle JA. A rapid in vivo test for chromosomal damage. Mutat Res. 1973;18:187–190
  89. Mavournin KH, Blakey DH, Cimino , et al. The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res. 1990;239:29–80
  90. Hayashi M, Tice RR, Macgregor JT, et al. In vivo rodent erythrocyte micronucleus assay. Mutat Res. 1994;312:293–304
  91. Arndt PA, Garratty G, Hill J, et al. Two cases of immune haemolytic anaemia, associated with anti-piperacillin, detected by the ‘immune complex’ method. Vox Sang. 2002;83:273–278
  92. Creech HJ, O'Connell AP. Immunochemistry of conjugates prepared from serum albumins and acridine nitrogen mustards (ICR mutagens). Cancer Res. 1981;41:3844–3851
  93. Dise CA, Burch JW, Goodman DB. Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid. J Biol Chem. 1982;257:4701–4704
  94. Chen RF. Fluorescence of quinacrine mustard conjugated to proteins. Arch Biochem Biophys. 1976;172:39–50
  95. Jusko WJ, Levy G. Plasma protein binding of riboflavin and riboflavin 5′-phosphate in man. J Pharm Sci. 1969;58:58–62
  96. Tapia G, Silva E. Photo-induced binding to the tryptophan residues of bovine and human serum albumin. Radiat Environ Biol. 1991;30:131–138
  97. Diaz M, Ines Becker M, De Ioannes AE, et al. Development of monoclonal antibodies against a riboflavin-tryptophan photoinduced adduct: Reactivity to eye lens proteins. J Photochem Photobiol. 1996;63:762–767
  98. Innis WSA, McCormick DB, Merrill AH. Variations in riboflavin binding by human plasma: Identification of immunoglobulins as the major proteins responsible. Biochem Med. 1985;34:151–156
  99. Merrill AH, Innis-Whitehouse WSA, McCormick DB. Characterization of human riboflavin-binding immunoglobulins. In:  Edmondson DE,  McCormick DB editor. Flavins and flavoproteins. Berlin: Walter de Gruyter & Co; 1987;p. 445–448
  100. International Organisation for Standardisation . International Standard ISO 10993 biological evaluation of medical devices—Part 5: Tests for in vitro cytotoxicity. Geneva, Switzerland: International Organisation for Standardisation; 1999;
  101. International Organisation for Standardisation . International Standard ISO 10993 biological evaluation of medical devices—Part 4: Selection of tests for interactions with blood. Geneva, Switzerland: International Organisation for Standardisation; 2002;
  102. Material Sciences Toxicology Laboratories . Autian method, ATTP-I. Memphis (TN): University of Tennessee Center for the Health Sciences; 1977;
  103. Hemolysis—Rabbit blood, evaluation of hemodialyzers and dialysis membranes. 77-1294, 213. 1977. DHEW Publication (NIH).
  104. Hellstern P, Sachse H, Schwinn H, et al. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang. 1992;63:178–185
  105. International Conference on Harmonisation of Technical Requirements for Pharmaceuticals (ICH) . S3B Pharmacokinetics: Guidance for Repeat Dose Tissue Distribution Studies. Geneva, Switzerland: ICH; 1995;
  106. Goodrich RP, Edrich RA, Li J, et al. The Mirasol PRT System for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apheresis Sci. 2006;35:5–17
  107. Goodrich RP, Edrich RA, Goodrich L, et al. The antiviral and antibacterial properties of riboflavin and light: Applications to blood safety and transfusion medicine. In:  Silva E,  Edwards AM editor. Flavins: Photochemistry and photobiology. Cambridge (UK): The Royal Society of Chemistry; 2006;p. 83–113

PII: S0887-7963(07)00112-5

doi: 10.1016/j.tmrv.2007.12.003

Transfusion Medicine Reviews
Volume 22, Issue 2 , Pages 133-153 , April 2008

Article Tools

* Image Usage & Resolution